Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 3Unknown 2Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoblastic Lymphadenopathy 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Hodgkin Disease 2Sezary Syndrome 1Recurrence 1Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Bronchiolitis Obliterans Syndrome 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 5fludarabine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3fludarabine phosphate 2endostar protein 2Melphalan 2Etoposide 2Doxorubicin 2Cisplatin 2Alemtuzumab 2thymoglobulin 1spartalizumab 1selinexor 1pembrolizumab 1Vindesine 1Vincristine 1Sensitivity and Specificity 1Rituximab 1Prednisone 1Prednisolone 1Methylprednisolone 1Interleukin-2 1Flavin-Adenine Dinucleotide 1Epirubicin 1Endostatins 1Drug Therapy 1Dexamethasone 1Cytarabine 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell × Alemtuzumab × Clear all
NCT05557903 2022-09-28

Phase â…  Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Lanzhou Institute of Biological Products Co., Ltd

Phase 1 Unknown
71 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT00725231 2012-05-07

A-CHOP-14

University of Göttingen

Phase 3 Unknown
274 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡